Biology subjects

Sanz-Nogues, C.

Publications and source records attributed to Sanz-Nogues, C..

3 recordsLinked to original sources

bioRxiv2026

Multi-modal MRI characterisation of vascular remodelling, muscle fibre integrity, and inflammatory recovery in a hindlimb ischaemia mouse model

The hindlimb ischaemia (HLI) mouse model is a widely used preclinical model of chronic limb-threatening ischaemia (CLTI). While CLTI involves complex interactions between impaired perfusion, inflammation and muscle wasting, the standard imaging approach, laser Doppler imaging (LDI), only assesses perfusion. MRI is used clinically to assess neural tracts, inflammation, and perfusion in the brain. We therefore evaluated whether a multimodal MRI approach could longitudinally monitor recovery in the HLI mouse model. Mice underwent MRI three days pre-HLI surgery, and on Days +3 and +7 post-surgery, with histology on Day +7. The MRI detected significant increases in muscle volume and inflammation after HLI surgery, with significant decreases in perfusion, vascular length, and muscle fibre integrity. Overall, MRI can monitor inflammation, muscle fibre integrity, and vascular recovery post-HLI and should be applied in future studies to identify mechanisms of therapeutic recovery in a sequential in vivo analysis without requiring animal sacrifice. O_FIG O_LINKSMALLFIG WIDTH=186 HEIGHT=200 SRC="FIGDIR/small/739107v1_ufig1.gif" ALT="Figure 1"> View larger version (45K): org.highwire.dtl.DTLVardef@100e5d1org.highwire.dtl.DTLVardef@1f0188dorg.highwire.dtl.DTLVardef@1dbdf4forg.highwire.dtl.DTLVardef@21d415_HPS_FORMAT_FIGEXP M_FIG O_FLOATNOGraphical AbstractC_FLOATNO C_FIG

biophysics↗

bioRxiv2025

An Assessment of the Functional State of Endothelial Colony Forming Cells from Patients with Diabetes Mellitus and Chronic Limb Threatening Ischemia

Chronic limb threatening ischemia (CLTI) is the most severe form of peripheral vascular disease which can lead to amputation with a high associated mortality rate. Endothelial colony forming cells (ECFCs) show potential as a cell therapy to revascularize the limbs of individuals with CLTI. However, autologous ECFCs from patient peripheral blood (PB) have been reported to have a dysfunctional phenotype. We investigated this disease phenotype in individuals with CLTI, with and without diabetes mellitus (DM), to determine ECFC suitability as an autologous cell therapy. PB-ECFCs were isolated from age-matched controls, individuals with DM, and individuals with CLTI, with and without DM. The frequency of isolating ECFCs from this donor cohort was calculated. Furthermore, in vitro characterization assays were performed (growth kinetics, angiogenic properties, and reactive oxygen species (ROS) levels) and compared between donor groups. We report a significantly increased frequency of ECFCs from individuals with CLTI, with and without DM. Furthermore, our results demonstrate no significant disease related effect on the in vitro functional properties of ECFCs between cohorts. However, there is a significantly higher in vitro angiogenic capacity in individuals with DM vs age-matched controls. Our results demonstrate that ECFCs can be isolated in individuals with CLTI, with and without DM, and that ECFC functionality is similar between cohorts. Therefore, if the 70% isolation efficiency from CLTI cohorts is overcome, then autologous PB-ECFCs may be a suitable therapeutic for CLTI. Further analysis is needed to determine the critical quality attributes of ECFCs from this patient population. Significance StatementTo the authors knowledge, this paper shows for the first time that endothelial colony forming cells can be isolated from individuals with chronic limb threatening ischemia, with and without diabetes. Additionally, we show a significantly higher frequency of endothelial colony forming cells isolated from chronic limb threatening ischemia patient cohorts. There is no significant difference in endothelial colony forming cells between age-matched controls and chronic limb threatening ischemia patient with and without diabetes mellitus in vitro, potentially suggesting an autologous approach may be a viable therapeutic option in the future.

cell biology↗

bioRxiv2025

miR-379-3p counteracts cancer cachexia through regulation of pyrimidinergic receptor, mitochondrial stress and interferon response.

Cancer cachexia is a highly prevalent wasting syndrome in cancer patients. Inflammation is hallmarks of symptomatic cachexia, however early stages of cachexia are not well understood, including differences between biological sexes. In a mouse model of early cachexia, muscle from males showed strong mitochondrial defects, whereas females were characterized by inflammatory and stress response. We demonstrate a novel link between the increase in purinergic receptor P26Y, and dysregulated Ca2+ homeostasis, mitochondrial dysfunction and damage, and inflammation during early stages of cancer cachexia. Low levels of miR-379-3p were associated with poor survival of patients with lung cancer. Restoring miR-379-3p levels in mice prevented loss of muscle mass and function. miR-379-3p targeted P2r6y and restored mitochondrial content and function, inhibited type II interferon response, and regulated the expression of Ca2+-related and apoptotic markers. This supports miR-379-3p as a hub regulating multiple processes underlying cachexia and represent a therapeutic target for cancer patients.

cancer biology↗